IDEXX Laboratories (NASDAQ:IDXX) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of IDEXX Laboratories (NASDAQ:IDXX) from a buy rating to a strong-buy rating in a research note released on Saturday morning.

A number of other brokerages have also issued reports on IDXX. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Barclays cut their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday. BTIG Research decreased their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Jefferies Financial Group restated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Finally, Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $777.78.

IDEXX Laboratories Stock Up 0.2%

Shares of IDXX stock opened at $644.61 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.87. IDEXX Laboratories has a one year low of $356.14 and a one year high of $769.98. The company’s fifty day moving average price is $693.74 and its 200-day moving average price is $664.98. The company has a market capitalization of $51.47 billion, a price-to-earnings ratio of 49.32, a PEG ratio of 3.93 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business posted $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts expect that IDEXX Laboratories will post 11.93 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. EverSource Wealth Advisors LLC increased its position in shares of IDEXX Laboratories by 14.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 713 shares of the company’s stock valued at $482,000 after purchasing an additional 92 shares during the last quarter. Americana Partners LLC increased its position in IDEXX Laboratories by 228.7% during the fourth quarter. Americana Partners LLC now owns 4,520 shares of the company’s stock valued at $3,058,000 after acquiring an additional 3,145 shares during the last quarter. Lloyd Advisory Services LLC. purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $48,000. Evoke Wealth LLC lifted its holdings in shares of IDEXX Laboratories by 10.7% in the 4th quarter. Evoke Wealth LLC now owns 436 shares of the company’s stock worth $295,000 after acquiring an additional 42 shares during the last quarter. Finally, Keudell Morrison Wealth Management bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $265,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.